1-3 of 3
Steven Hua
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Michinori Ogura, Toshiki Uchida, David A MacDonald, Kiyohiko Hatake, Andrew Davies, Randeep Sangha, Michael Crump, MD, FRCPC, Catherine Thieblemont, MD, Taro Ishibashi, Steven Hua, Luisa Paccagnella, Erik R Vandendries, MD, PhD, Yukio Kobayashi, Kensei Tobinai, MD
Journal: Blood
Blood (2011) 118 (21): 3715.
https://doi.org/10.1182/blood.V118.21.3715.3715
Published: 2011
Journal Articles

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD, Joseph Leach, MD, W. Christopher Ehmann, MD, Kiyoshi Ando, MD, PhD, Kiyohiko Hatake, MD, PhD, Kensei Tobinai, MD, PhD, Tatyana Feldman, MD, Steven Hua, Angela DG Volkert, Erik R. Vandendries, MD, PhD, Michinori Ogura, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 430.
https://doi.org/10.1182/blood.V116.21.430.430
Published: 2010
Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Nam H. Dang, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, MD, Gregor Verhoef, MD, Peter Johnson, MD, Ama Z S Rohatiner, MD, Jonathan L. Kaufman, MD, Eva Gine, M.D., Bertrand Coiffier, MD, Myron S Czuczman, MD, James Foran, MD, Simon Durrant, MD, Steven Hua, PhD, Erik R. Vandendries, MD, PhD, Luis Fayad, MD
Journal: Blood
Blood (2009) 114 (22): 584.
https://doi.org/10.1182/blood.V114.22.584.584
Published: 2009